An overview of current therapy options of non-alcoholic fatty liver disease

Czech version

Authors: Karel Dvořák ¹; Václav Šmíd ²
Authors‘ workplace: Oddělení gastroenterologie a hepatologie, Krajská nemocnice Liberec, a. s. ¹; 4. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze ²
Published in: Čas. Lék. čes. 2022; 161: 77-79
Category: Review Article

Overview

Finding an effective treatment of non-alcoholic fatty liver disease (NAFLD) remains one of main challenges in hepatological research for the 21^st century, since there is no such a treatment yet. Lifestyle modifications leading to weight reduction are cheap and effective, however only a fraction of patients reaches significant weight loss goals. Current pharmacological treatment of NAFLD comprises screening and therapy of metabolic syndrome components and minimizing of alcohol intake. There are new substances being evaluated in clinical trials, the most promising ones are semaglutide and lanifibranor.

Keywords:

Fatty liver – NAFLD – NASH – liver fibrosis – NAFLD treatment – GLP-1 agonists

Sources

Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51(1): 121–129.
Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017; 67(4): 829–846.
Memel ZN, Wang J, Corey KE. Intermittent fasting as a treatment for nonalcoholic fatty liver disease: What is the evidence? Clin Liver Dis (Hoboken) 2022; 19(3): 101–105.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149(2): 367–378.e5.
Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017; 29(2): e8–e12.
Keating SE, Hackett DA, George J et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57(1): 157–166.
Helajarvi H, Pahkala K, Heinonen OJ et al. Television viewing and fatty liver in early midlife. The Cardiovascular Risk in Young Finns Study. Ann Med 2015; 47(6): 519–526.
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362(18): 1675–1685.
Klein EA, Thompson IM Jr, Tangen CM et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306(14): 1549–1556.
Kuchay MS, Misra A. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. Diabetes Metab Syndr 2022; 16(3): 102446.
Akuta N, Kawamura Y, Fujiyama S et al. SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: The Long-term effects on clinical features and liver histopathology. Intern Med 2020; 59(16): 1931–1937.
Armstrong MJ, Hull D, Guo K et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016; 64(2): 399–408.
Lee JI, Lee HW, Lee KS et al. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study. Am J Gastroenterol 2021; 116(1): 116–124.
de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clin Nutr 2018; 37(1): 37–55.
Campbell P, Symonds A, Barritt AS. Therapy for nonalcoholic fatty liver disease: current options and future directions. Clin Ther 2021; 43(3): 500–517.

Labels

Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist

ÚVODEM

EDITORIAL

Liver tests

Diagnostic methods of fatty liver diseases

Liver elastography

Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD – common aspects of pathogenesis

Diagnosis of non-alcoholic fatty liver disease and its active screening in risk groups

Statins and liver

Current hepatitis C therapy

Klinická obezitologie – nejen Základy

Dietary habits in students from the medical faculties

Za profesorem Peterem Krištúfkem, čestným prezidentem SLS

Article was published in

Journal of Czech Physicians

2022 Issue 2